JAVIER
HORNEDO MUGUIRO
PROFESOR
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (30)
2020
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
2018
2009
2006
-
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902
-
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support
Journal of Clinical Oncology, Vol. 24, Núm. 22, pp. 3611-3618
-
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 889-895
2005
-
Cancer-related anemia: Pathogenesis, prevalence and treatment
Oncology
-
It is not time to stop progesterone receptor testing in breast cancer [16]
Journal of Clinical Oncology
2004
-
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain
Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206
-
Initially Metastatic Breast Carcinoma Has a Distinct Disease Pattern but an Equivalent Outcome Compared with Recurrent Metastatic Breast Carcinoma
Cancer, Vol. 100, Núm. 9, pp. 1833-1842
2003
-
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer
Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291
-
Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy
Leukemia, Vol. 17, Núm. 2, pp. 437-441
2002
-
Dynamic filters for the spectral analysis of random signals
Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551
-
The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period
Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743
2001
-
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
Journal of the National Cancer Institute, Vol. 93, Núm. 1, pp. 31-38
-
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: A phase I trial
Bone Marrow Transplantation, Vol. 27, Núm. 2, pp. 117-123
-
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: A Phase II multicentric trial
Cancer, Vol. 92, Núm. 10, pp. 2508-2516
-
Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide
Leukemia, Vol. 15, Núm. 3, pp. 430-439
2000
-
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial
Journal of Clinical Oncology, Vol. 18, Núm. 10, pp. 2126-2134
1999
-
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial
Cancer, Vol. 85, Núm. 1, pp. 213-219